LBRX LB PHARMACEUTICALS INC Insider Trading

Vida Ventures GP III acquired 333,333 shares for $4,999,995.00 at $15.00 in 2 separate purchases on LBRX's 4th trading day.

Vida Ventures GP III, a 10% owner, executed 2 transactions totaling 333,333 shares for $4,999,995.00 at $15.00 per share on the company's fourth trading day post-IPO. The timing and scale—a precisely $5.0M investment in exactly 333,333 shares—suggests a deliberate capital commitment during the initial public market window. This activity occurs within a broader cluster pattern: 3 other insiders also bought within the past 14 days, indicating coordinated accumulation by multiple parties at or near the IPO price. The current price of $15.78 sits above the transaction price, but with only 4 trading days elapsed, this early price action alone is not yet a meaningful signal. The FLAG indicates this filing involves derivative security conversion rather than a straightforward equity purchase; the insider's full economic position includes holdings in Table II (derivative securities) not yet available in this database, so the reported 2,029 post-transaction shares in Table I do not capture the complete position.

Deep Track Biotech acquires 2,666,666 shares for $39,999,990.00 at $15.00; derivative conversion underway

Deep Track Biotechnology Master Fund, Ltd., a 10% owner, executed 2 separate purchases totaling 2,666,666 shares for $39,999,990.00 at $15.00 per share on 2025-09-12, the day of LBRX's recent listing (4 trading days prior to filing). This is a material capital commitment by a significant shareholder in a newly public company at its IPO reference price. The transaction is marked as a derivative-conversion event, meaning the insider's full position includes unreported derivative holdings in Form 4 Table II; the 666,666 shares showing post-transaction reflect only the converted equity portion, not the complete economic position. The cluster pattern shows 3 other insiders also acquired shares within the past 14 days, indicating broad insider appetite at current levels. Investors should monitor derivative position disclosures and track whether this cluster of acquisitions continues as LBRX trades post-listing.

Director Nussbaum bought 1,000,000 shares of LBRX at $15.00 ($15.0M) in cluster with 3 other insiders in 14 days

Director Ran Nussbaum purchased 1,000,000 shares at $15.00 on 2025-09-12, increasing his position from 411,681 shares to 1,411,681 shares and representing a 242.9% increase relative to pre-transaction holdings. This purchase occurred as part of a cluster pattern, with 3 other insiders also buying within the past 14 days, suggesting coordinated board-level confidence in the stock shortly after its recent listing. The stock now trades at $15.78 as of 2025-09-16, four trading days post-purchase. The filing contains a derivative-conversion transaction; the insider's full position may include derivative securities not yet reflected in available Form 4 Table II data, so this $15.0M equity purchase represents a portion of his total investment activity, not necessarily his complete position change.

10% Owner Pontifax Management buys 1,000,000 shares (1.00M) of LBRX at $15.00 in $15.0M transaction; 3 other insiders also bought within 14 days

Pontifax Management 4 G.P. (2015) Ltd., a 10% owner, purchased 1,000,000 shares of LB Pharmaceuticals at $15.00 per share for a total value of $15,000,000.00, increasing its holdings from 411,681 shares to 1,411,681 shares (+242.9%). This purchase is notable because it represents a substantial commitment of capital by a significant stakeholder immediately following the company's recent listing (4 trading days ago). The transaction occurred alongside a cluster pattern: 3 other insiders also bought within the past 14 days. This synchronized insider accumulation at the company's early post-IPO stage, combined with the magnitude of the principal owner's stake increase, suggests broad internal alignment on valuation shortly after public market entry.